SIOP 2025: Latest data of zurletrectinib (ICP-723) for the treatment of pediatric and adolescent patients with advanced solid tumors announced
Professor Yizhuo Zhang, from the Department of Pediatric Oncology at the Sun Yat-sen University Cancer Center, is the leading PI of the study. Professor Juan Wang, representing the multicenter investigators team, delivered an oral presentation at the Congress entitled “Safety, pharmacokinetics, and efficacy of zurletrectinib, a next-generation pan-TRK inhibitor, in pediatric and adolescent patients with advanced solid tumor: a Phase I/II trial”.
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.